2024
Mood lability and depression limit oral contraceptive therapy in endometriosis
Cevik E, Taylor H. Mood lability and depression limit oral contraceptive therapy in endometriosis. Fertility And Sterility 2024, 123: 838-845. PMID: 39672361, DOI: 10.1016/j.fertnstert.2024.12.011.Peer-Reviewed Original ResearchProgestin-only oral contraceptivesOral contraceptivesOC discontinuationOC useDiagnosis of depressionMood labilityEffects of oral contraceptivesOral contraceptive (OCDocumented diagnosis of depressionDiscontinued OC useEffect of OC useInternational Classification of Diseases-10 codesSide effects of OC useElectronic medical record reviewTreated with OCCourse of treatmentMedical record reviewIncreased incidence of depressionUniversity affiliated hospitalTreatment discontinuationIncidence of depressionEndometriosisStudy cohortPrimary outcomeIncreased incidenceORAL CORTICOSTEROID USAGE PATTERNS IN PATIENTS WITH ASTHMA INITIATING DUPILUMAB: THE RAPID REGISTRY STUDY
Mosnaim G, Lugogo N, Heffler E, Plaza V, Hilberg O, Xia C, DePrado-Gomez L, Kwah J. ORAL CORTICOSTEROID USAGE PATTERNS IN PATIENTS WITH ASTHMA INITIATING DUPILUMAB: THE RAPID REGISTRY STUDY. Annals Of Allergy Asthma & Immunology 2024, 133: s46. DOI: 10.1016/j.anai.2024.08.168.Peer-Reviewed Original ResearchOral corticosteroid useOral corticosteroidsPre-study periodOC useOC usageLong-term OC useStudy periodPatterns of OC useAssociated with significant adverse eventsOral corticosteroid burdenYear prior to enrollmentSignificant adverse eventsPercentage of patientsOverall healthcare burdenAsthma-related eventsReal-world studyMaintenance therapySevere exacerbationsDupilumabAdverse eventsStudy entryRegistry studyGlobal RegistryPrescribing informationTreatment daysRacial and ethnic differences in epithelial ovarian cancer risk: an analysis from the Ovarian Cancer Association Consortium
Meagher N, White K, Wilkens L, Bandera E, Berchuck A, Carney M, Cramer D, Cushing-Haugen K, Jordan S, Kaufmann S, Le N, Pike M, Riggan M, Qin B, Rothstein J, Titus L, Winham S, Anton-Culver H, Doherty J, Goode E, Pearce C, Risch H, Webb P, Cook L, Goodman M, Harris H, Le Marchand L, McGuire V, Pharoah P, Sarink D, Schildkraut J, Sieh W, Terry K, Thompson P, Whittemore A, Wu A, Peres L, Merritt M. Racial and ethnic differences in epithelial ovarian cancer risk: an analysis from the Ovarian Cancer Association Consortium. American Journal Of Epidemiology 2024, 193: 1242-1252. PMID: 38775277, PMCID: PMC11369223, DOI: 10.1093/aje/kwae076.Peer-Reviewed Original ResearchConceptsOvarian Cancer Association ConsortiumEpithelial ovarian cancer riskNative Hawaiian/Pacific IslanderEpithelial ovarian cancerInverse associationHawaiian/Pacific IslanderRisk associationOdds ratioOvarian cancer riskRisk factor associationsTubal ligationLogistic regression modelsOral contraceptive (OCIslander womenCancer riskFactor associationsWhite participantsPrevention strategiesAsian womenOC useEthnic differencesRisk factorsGynecologic cancerRegression modelsOvarian cancer
2023
Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
Pavord I, Gardiner F, Heaney L, Domingo C, Price R, Pullan A, Oppenheimer J, Brusselle G, Nagase H, Chupp G, Pizzichini E, Bañas-Conejero D, Howarth P. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study. Frontiers In Immunology 2023, 14: 1150162. PMID: 37122713, PMCID: PMC10131245, DOI: 10.3389/fimmu.2023.1150162.Peer-Reviewed Original ResearchConceptsSevere eosinophilic asthmaClinical remissionEosinophilic asthmaRemission definitionsClinical practiceAsthma Control Test scoresBetter ACT scoresProportion of patientsSubset of patientsACT scoreMepolizumab therapyMepolizumab treatmentOral corticosteroidsPrior exacerbationsOC useSevere asthmaBaseline characteristicsExpiratory volumeLung functionRemission outcomesMedical recordsDisease progressionTreatment outcomesRemissionTreatment goals
2017
Oral Contraceptives and Cigarette Smoking: A Review of the Literature and Future Directions
Allen AM, Weinberger AH, Wetherill RR, Howe CL, McKee SA. Oral Contraceptives and Cigarette Smoking: A Review of the Literature and Future Directions. Nicotine & Tobacco Research 2017, 21: 592-601. PMID: 29165663, PMCID: PMC6468133, DOI: 10.1093/ntr/ntx258.Peer-Reviewed Original ResearchConceptsSmoking-related outcomesOC useOral contraceptivesSmoking cessation outcomesCessation outcomesOC usersNovel smoking cessation interventionUse of OCsNicotine metabolismWeight gainSmoking-related symptomsEndogenous sex hormonesSmoking cessation interventionFaster nicotine metabolismCross-sectional studyPhysiological stress responsePremenopausal smokersCurrent smokingPremenopausal womenCessation interventionsCigarette smokingEstradiol levelsSex hormonesGreater oddsFollowing keywords
2016
Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors
Merritt MA, Strickler HD, Einstein MH, Yang HP, Sherman ME, Wentzensen N, Brouwer-Visser J, Cossio MJ, Whitney KD, Yu H, Gunter MJ, Huang GS. Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors. Cancer Causes & Control 2016, 27: 737-748. PMID: 27125830, PMCID: PMC4870288, DOI: 10.1007/s10552-016-0751-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedDiabetes MellitusEndometrial NeoplasmsEndometriumEstrogen Receptor alphaEstrogensFemaleGene ExpressionGonadal Steroid HormonesHumansImmunohistochemistryInsulinInsulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IInsulin-Like Growth Factor IIMiddle AgedParityPhosphoproteinsPostmenopausePremenopausePTEN PhosphohydrolaseReal-Time Polymerase Chain ReactionReceptor, IGF Type 1Receptor, InsulinReceptors, ProgesteroneReceptors, SomatomedinRisk FactorsRNA, MessengerConceptsInsulin-like growth factorEndometrial cancer risk factorsCancer risk factorsPostmenopausal womenRisk factorsEndometrial tissueInsulin/insulin-like growth factorRegular nonsteroidal anti-inflammatory drug useNonsteroidal anti-inflammatory drug usePhosphorylated insulin-like growth factorEstrogen receptor-positive tissuesAnti-inflammatory drug useNon-diabetic womenProtein levelsReceptor-positive tissuesNormal endometrial tissuesHigher IGFBP1OC usePostmenopausal endometriumBenign indicationsProgesterone receptorQuantitative real-time PCRHormone axesIGFBP3 expressionHuman endometrium
2013
Oral Contraceptives and Risk of Ovarian Cancer and Breast Cancer Among High-Risk Women: A Systematic Review and Meta-Analysis
Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral Contraceptives and Risk of Ovarian Cancer and Breast Cancer Among High-Risk Women: A Systematic Review and Meta-Analysis. Journal Of Clinical Oncology 2013, 31: 4188-4198. PMID: 24145348, DOI: 10.1200/jco.2013.48.9021.Peer-Reviewed Original ResearchConceptsBRCA1/2 mutation carriersBRCA2 mutation carriersOvarian cancerBreast cancerMutation carriersFamily historyOC useCancer riskSystematic reviewOral contraceptive useHigh-risk womenUse of OCsBreast cancer riskOvarian cancer riskStrong family historyTiming of useOral contraceptivesCochrane DatabaseInverse associationBRCA1/2 mutationsContraceptive useElevated riskGeneral populationUnique citationsMeta-analysisOral contraceptive use for the primary prevention of ovarian cancer.
Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Urrutia RP, Lowery WJ, Dinan M, McBroom AJ, Wing L, Musty MD, Lallinger KR, Hasselblad V, Sanders GD, Myers ER. Oral contraceptive use for the primary prevention of ovarian cancer. Evidence Report Technology Assessment 2013, 1-514. PMID: 24423062, PMCID: PMC4781074.Peer-Reviewed Original ResearchConceptsOvarian cancer preventionOral contraceptivesVascular eventsOvarian cancerOC useOC usersPrimary preventionHarm/benefit ratioCervical cancerColorectal cancerCancer incidenceCancer preventionUse of OCsPersistent human papillomavirus (HPV) infectionCurrent OC usersBenefit ratioHuman papillomavirus infectionOral contraceptive useBreast cancer incidenceOvarian cancer incidenceLife expectancyOvarian cancer outcomeRisk of breastRandom-effects modelEnglish-language studies
2003
Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States)
Modugno F, Moslehi R, Ness RB, Nelson DB, Belle S, Kant JA, Wheeler JE, Wonderlick A, Fishman D, Karlan B, Risch H, Cramer DW, Dube MP, Narod SA. Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). Cancer Causes & Control 2003, 14: 439-446. PMID: 12946038, DOI: 10.1023/a:1024932427503.Peer-Reviewed Original ResearchConceptsBRCA1 carriersOC useTubal ligationOvarian cancerReproductive factorsInvasive epithelial ovarian cancerFounder mutationOral contraceptive useHistory of breastfeedingEpithelial ovarian cancerOvarian cancer casesOvarian cancer riskBRCA1 founder mutationsBRCA2 mutation carriersAshkenazi founder mutationsCase-only studyNulliparous womenGynecologic surgeryBRCA1/2 carriersRisk factorsBRCA2 mutationsCancer casesLive birthsBRCA1/2 mutationsContraceptive use
1999
Oral contraceptive use and risk of melanoma in premenopausal women
Feskanich D, Hunter DJ, Willett WC, Spiegelman D, Stampfer MJ, Speizer FE, Colditz GA. Oral contraceptive use and risk of melanoma in premenopausal women. British Journal Of Cancer 1999, 81: 918-923. PMID: 10555769, PMCID: PMC2374297, DOI: 10.1038/sj.bjc.6690787.Peer-Reviewed Original ResearchConceptsCurrent OC usersOral contraceptive useRisk of melanomaOC usersRisk factorsContraceptive useSun exposureHealth Study II cohortLow-dose oestrogen pillsPast OC usersBody mass indexPossible risk factorsLonger durationPremenopausal white womenLogistic regression modelsNHS IIOC usePremenopausal womenSignificant twofold increaseMass indexSuperficial spreadingNodular melanomaSkin reactionsIncidence rateSunburn history
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply